Cayman Islands, January 15, 2025 — Silexion Therapeutics Corp (NASDAQ: SLXN ) (Silexion Therapeutics or the Company), a clinical-stage biotechnology company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced pricing of public offer of a total of 3,703,703 ordinary shares of the Company (or equivalents of ordinary shares) and guarantees for the purchase of up to 3,703,703 of common stock at a combined public offering price of $1.35 per share (or common stock equivalent) and the associated warrant. The warrants will have an exercise price of $1.35 per share, will be exercisable immediately upon issuance, and will expire five years from the date of issuance. The offering is expected to close on or about January 17, 2025, subject to the satisfaction of customary closing conditions.
HC Wainwright & Co. is acting as the exclusive placement agent for the offering.
Gross proceeds from the offering, before deducting placement agent fees and other offering expenses, are expected to be approximately $5.0 million. The Company intends to use the net proceeds from this offering to advance the Company’s preclinical studies and for general corporate purposes.
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-282932), which has been declared effective by the Securities and Exchange Commission (SEC) on January 15, 2025. The offering is being made by means of a prospectus only which forms part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained from the SEC’s website at http://www.sec.gov and may also be obtained by contacting HC Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or by email at placements@hcwco.com.
This press release will not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sale of those securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of any such state or other jurisdiction.
About Silexion Therapeutics
Silexion Therapeutics is a pioneering oncology-focused clinical biotechnology company developing innovative RNA interference (RNAi) therapies for the treatment of solid tumors driven by mutations in KRAS, the most common oncogenic driver of human cancer. The company’s first-generation product, LODER™, showed promising results in a phase 2 trial in unresectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information, visit: https://silexion.com
Notice of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions in connection with the offering and the intended use of the net proceeds of the offering. These forward-looking statements are generally identified by terminology such as “may,” “should,” “could,” “could,” “plan,” “possible,” “project,” “endeavor,” ” budget”, “anticipate” “, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “anticipate”, “potential” or “continue”, or negative words of these terms or their variations or similar forward-looking statements involve numerous risks, uncertainties and assumptions, and actual results or events may differ materially from those anticipated or implied in such statements. Important factors that may cause such differences include, but are not limited to: (i ) Silexion’s ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion’s strategy, future operations, financial position, anticipated costs and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; and (vi) other risks and uncertainties set forth in documents the company has filed or will file with the SEC, including the proxy statement/prospectus filed with the SEC on July 17, 2024. Silexion cautions you not to place undue reliance on forward-looking statements that forward-looking statements, which reflect current beliefs and are based on information currently available on the date the forward-looking statement is made. The forward-looking statements made herein speak only as of the date on which they are made. Silexion undertakes no obligation to revise any forward-looking statements to reflect future events, changes in circumstances or changes in beliefs, except as otherwise required by law.
Company contact:
Silexion Therapeutics Corp
Mrs. Mirit Horenshtein Hadar, financial director
mirit@silexion.com
Capital market advisors for Silexion:
Arx | Capital market advisors
Desk for raising capital
silexion@arxadvisory.com
